Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

STXS 10.21.2024

Full Press ReleaseSEC FilingsOur STXS Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
  • 01.06.2025 - Patricia Williams
  • 12.09.2024 - Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA

Recent Filings

  • 01.02.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

ST. LOUIS,Oct. 21, 2024(GLOBE NEWSWIRE) --Stereotaxis(NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s Annual Meeting taking placeOctober 28-29inLisbon, Portugal.

The global physician-ledSociety for Cardiac Robotic Navigation(SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology.

The SCRN conference includes a faculty of over forty physicians, including pioneering key opinion leaders in the field, from acrossNorth America,Europe, andAsia. Stereotaxis’ robotic technologies will be highlighted in presentations, panels, and demonstrations throughout the conference. Topics range from the use and value of robotics across a range of clinical applications, new technology developments, and the broader context of robotics in endovascular interventions. Highlighted topics include:

  • Developments with artificial intelligence, digitization of the operation room, and robotic automation
  • Clinical experience with the MAGiC ablation catheter and Abbott’s EnSite X mapping system
  • Additional robotic catheter innovations including high-density mapping and pulsed field ablation
  • Robotic system innovations with Genesis and GenesisX
  • Alternative access from the arm rather than the groin
  • Clinical value and best practices for robotics in treating complex arrhythmia

“We are excited to join SCRN this year and look forward to a particularly relevant and interesting agenda,” saidDavid Fischel,StereotaxisChairman and CEO. “The strength and momentum of SCRN is reflective of the growing appreciation for the importance of robotics in advancing the cardiology community.”

AboutStereotaxisStereotaxis(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room.Stereotaxistechnology has been used to treat over 100,000 patients acrossthe United States,Europe,Asia, and elsewhere. For more information, please visitwww.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with theSecurities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:David L. FischelChairman and Chief Executive Officer

Kimberly PeeryChief Financial Officer

314-678-6100Investors@Stereotaxis.com

Primary Logo

Source: Stereotaxis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com